Role of macrophage targeting in the antitumor activity of trabectedin.

[1]  J. Blay,et al.  A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. , 2012, European journal of cancer.

[2]  T. Welte,et al.  TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice , 2012, The Journal of experimental medicine.

[3]  C. Benedict,et al.  TRAIL: not just for tumors anymore? , 2012, The Journal of experimental medicine.

[4]  J. Hong,et al.  Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins , 2012, Apoptosis.

[5]  M. Siegelin.  Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis , 2012, Expert opinion on therapeutic targets.

[6]  A. Yang,et al.  Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. , 2012, Cancer cell.

[7]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[8]  C. Cordon-Cardo,et al.  PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. , 2012, The Journal of clinical investigation.

[9]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[10]  P. Allavena,et al.  Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment , 2012, Clinical and experimental immunology.

[11]  S. Biswas,et al.  Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice , 2012, Journal of leukocyte biology.

[12]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[13]  G. Gores,et al.  Death Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis* , 2011, The Journal of Biological Chemistry.

[14]  O. Micheau,et al.  Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion , 2011, Recent patents on anti-cancer drug discovery.

[15]  Michael Karin,et al.  Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.

[16]  F. Finkelman,et al.  Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a Signature of TH2 Inflammation , 2011, Science.

[17]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[18]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[19]  S. Oh,et al.  Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. , 2011, Carcinogenesis.

[20]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[21]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[22]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[24]  C. Galmarini,et al.  A Review of Trabectedin (ET-743): A Unique Mechanism of Action , 2010, Molecular Cancer Therapeutics.

[25]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[26]  P. Casali,et al.  Trabectedin therapy for sarcomas , 2010, Current opinion in oncology.

[27]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Alberto Mantovani,et al.  Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility , 2010, The Journal of Immunology.

[29]  K. Pienta,et al.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.

[30]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[31]  A. Mantovani,et al.  Cancer and Inflammation: Implications for Pharmacology and Therapeutics , 2010, Clinical pharmacology and therapeutics.

[32]  P. Allavena,et al.  Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. , 2010, Cancer research.

[33]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[34]  N. Ferrara.  Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis , 2010, Current opinion in hematology.

[35]  S. Keam,et al.  Trabectedin , 2010, Drugs.

[36]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[37]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[38]  M. Hebbar,et al.  Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages , 2009, International journal of cancer.

[39]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[40]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[41]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[42]  F. Grosso,et al.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors , 2009, Molecular Cancer Therapeutics.

[43]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[44]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[45]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[46]  D. Noonan,et al.  Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.

[47]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[48]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[49]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[50]  P. Libby,et al.  Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. , 2007, The Journal of clinical investigation.

[51]  A. Sica,et al.  p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. , 2006, Cancer research.

[52]  G. Screaton,et al.  Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Lifson,et al.  CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. , 2005, Blood.

[54]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[55]  P. Allavena,et al.  Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. , 2005, Cancer research.

[56]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[57]  L. Lenz,et al.  TRAIL-R as a negative regulator of innate immune cell responses. , 2004, Immunity.

[58]  N. Van Rooijen,et al.  "In vivo" depletion of macrophages by liposome-mediated "suicide". , 2003, Methods in enzymology.

[59]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[60]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[61]  M D'Incalci,et al.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. , 2001, European journal of cancer.

[62]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[63]  R. Mantovani,et al.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[65]  A. Mantovani,et al.  A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. , 1990, Journal of immunology.

[66]  A. Mantovani,et al.  Regulation of the macrophage content of neoplasms by chemoattractants. , 1983, Science.

[67]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.